✦ LIBER ✦

Risk management of biosimilars in oncology

✍ Scribed by A. G. Vulto

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Risk management of biosimilars in oncolo

✍ Arnold G. Vulto; Stacy A. Crow 📂 Article 📅 2012 🏛 Springer-Verlag 🌐 English ⚖ 121 KB

Erythropoietin biosimilars currently ava

✍ Didier Kamioner 📂 Article 📅 2012 🏛 Springer-Verlag 🌐 English ⚖ 139 KB

Presently available biosimilars in hemat

✍ Pere Gascon 📂 Article 📅 2012 🏛 Springer-Verlag 🌐 English ⚖ 102 KB

Biosimilars and their use in hematology

✍ Cornelius F. Waller 📂 Article 📅 2012 🏛 Frontline Medical Communications, Inc. 🌐 English ⚖ 702 KB

Biosimilar agents in oncology/haematolog

✍ Dietger Niederwieser; Stephan Schmitz 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 214 KB

Presently available biosimilars in hemat

✍ P. Gascon 📂 Article 📅 2011 🏛 Springer-Verlag 🌐 French ⚖ 89 KB